Clinical Trials
8 trialsNCT00360828 2017-03-23
Phase II Study of Irinotecan HCI for Recurrent Anaplastic Astrocytomas, Mixed Malignant Gliomas, and Oligodendrogliomas
H. Lee Moffitt Cancer Center and Research Institute
Phase 2 Terminated
NCT00003134 2016-12-07
Irinotecan in Treating Patients With Recurrent Glioma
Alliance for Clinical Trials in Oncology
Phase 2 Completed
NCT00616005 2014-08-18
Ph. II Treatment of Adults w Primary Malignant Glioma w Irinotecan + Temozolomide
Duke University
Phase 2 Completed
NCT00352521 2014-07-22
Dynamic Contrast-Enhanced Magnetic Resonance Imaging (DCE-MRI) With Bevacizumab and Irinotecan for Malignant Glioma
Duke University
Phase 2 Completed
NCT00268359 2014-07-21
Bevacizumab and Irinotecan in Treating Patients With Recurrent or Refractory Gliomas
Duke University
Phase 2 Completed
NCT00921167 2013-12-04
A Study to Evaluate the Efficacy of Bevacizumab Plus Irinotecan in Recurrent Gliomas
Clinical Research Center for Solid Tumor, Korea
Phase 2 Completed
NCT00004078 2013-06-14
Irinotecan in Treating Children With Refractory Solid Tumors
Children's Oncology Group
Phase 2 Completed
NCT00004068 2011-10-04
Irinotecan Followed by Radiation Therapy and Temozolomide in Treating Children With Newly Diagnosed Brain Tumor
St. Jude Children's Research Hospital
Phase 2 Completed